miR Scientific announces FDA Breakthrough Device Designation for its Prostate Cancer Liquid Biopsy Test October 26, 2020 miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that it has received Breakthrough Device Designation by the U.S Food & Drug Administration for its miR Sentinel™ PCC4 Assay (miR Sentinel™ Prostate Test). FDA Breakthrough Device designation is granted to novel medical devices that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Read the full story here.Source: PR Newswire Prostate Cancer News
miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that it has received Breakthrough Device Designation by the U.S Food & Drug Administration for its miR Sentinel™ PCC4 Assay (miR Sentinel™ Prostate Test). FDA Breakthrough Device designation is granted to novel medical devices that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Read the full story here.Source: PR Newswire
Complete the Survey
